Tutorials › Statistical Genetics › Genome-Wide Significance Versus Strength of Evidence

Multiple Testing and Association Calibration · Tutorial 367 of 989

Genome-Wide Significance Versus Strength of Evidence

Learn why crossing a genome-wide threshold is not the same as having a large or certain effect, and how to read the evidence in context.

Intermediate 10 min read

What You'll Learn

  • Explain what a genome-wide significance threshold controls and why it should be prespecified.
  • Interpret a two-sided association p-value under its null model.
  • Compare evidence strength with effect size and precision.
  • Use confidence intervals to assess plausible effect sizes and uncertainty.
  • Evaluate what a replication result adds without treating it as automatic confirmation.

Significance Is a Decision Threshold, Not an Effect Size

A genome-wide association study may test hundreds of thousands or millions of genetic variants. A p-value that would look small in a single planned test can therefore be unsurprising somewhere in a genome-wide scan. A genome-wide significance threshold addresses this multiplicity: it sets a rule for deciding which results are sufficiently unusual under the testing procedure to be flagged. It does not measure how large an association is, how useful it is, or the probability that it is true.

Those questions require reading the association result as a whole. The p-value describes compatibility with a specified null model; the estimated effect describes the association's magnitude and direction on a stated scale; and the standard error and confidence interval describe its precision. Evidence from an independent replication can add support, but its interpretation depends on the replication design and its prespecified criteria.

Definition: A genome-wide significance threshold is a prespecified cutoff for p-values used to flag associations in a defined genome-wide testing family. For example, \(5\times10^{-8}\) is a widely used conventional cutoff, but it is not a universal law: a suitable threshold depends on the testing family and analysis plan. Strength of evidence refers to how incompatible the observed result is with a specified null model, as summarized by the p-value and its assumptions; it is not the effect's magnitude.

What the P-Value Says

For a particular variant, suppose the association model estimates an effect \(\hat{\beta}\), with standard error \(SE\), and tests \(H_0:\beta=0\). In a large sample, a Wald test uses the statistic \(Z=\hat{\beta}/SE\), which is approximately standard normal under the null and the model's assumptions. A two-sided p-value is the probability, assuming that null model, of obtaining a test statistic at least as far from zero as the observed statistic:

$$ Z=\frac{\hat{\beta}}{SE}, \qquad p=2\{1-\Phi(|Z|)\}, $$

where \(\Phi\) is the standard normal cumulative distribution function. The calculation assumes the chosen association model is appropriate, the standard error is valid, and the large-sample approximation is adequate. In a GWAS, sample structure, genotype quality, phenotype definition, and other design features matter because they affect whether the model and its uncertainty estimates are credible.

The p-value is not the probability that \(H_0\) is true, nor the probability that chance alone produced the data. It is calculated conditional on \(H_0\) and the statistical model. A smaller p-value indicates that the result is less compatible with that null model, but it does not by itself establish a causal effect or quantify the effect's importance.

From a Testing Family to a Threshold

The testing family must be defined before choosing a genome-wide cutoff: it specifies which hypotheses are being treated as one family for error control. For example, the family might include all tested variants for one phenotype under a stated analysis, or it might include a broader set of phenotypes and analyses. Bonferroni control provides a simple reference: for \(m\) tests and family-wise error target \(\alpha\), test each hypothesis at \(\alpha/m\). By the union bound, the probability of at least one false rejection is no greater than the sum of the individual probabilities, and hence no greater than \(\alpha\), when each null test is valid.

$$ P(\text{at least one false rejection}) \leq \sum_{j=1}^{m}P(\text{false rejection at test }j) \leq m\frac{\alpha}{m}=\alpha. $$

This bound does not require independent tests. In genetic data, linkage disequilibrium makes tests correlated, so Bonferroni can be conservative; nevertheless, its threshold gives a transparent benchmark. The commonly used \(5\times10^{-8}\) is a convention motivated by genome-wide testing, not an exact consequence of a fixed universal number of independent tests. A threshold is meaningful only in relation to the family and procedure it was chosen for.

Prespecification matters. If analysts select a threshold after seeing results, or silently expand the family to include additional phenotypes or analyses, the nominal error guarantee may no longer describe the full search. Conversely, crossing a stringent threshold says that the result passed a decision rule designed for a broad search; it does not imply a large effect.

Worked Examples: Threshold, Effect, and Precision

Worked Example: A Small Effect Can Have Strong Evidence

Suppose a hypothetical GWAS tests a quantitative trait standardized to have standard deviation 1. Under an additive dosage model, one additional copy of the effect allele is associated with an estimated trait difference of \(\hat{\beta}=0.080\) standard deviations, with \(SE=0.014\). Assume the model and large-sample Wald approximation are suitable, and that the prespecified genome-wide cutoff for this testing family is \(5\times10^{-8}\).

The test statistic is

$$ Z=\frac{0.080}{0.014}=5.714. $$

The two-sided p-value is approximately \(1.1\times10^{-8}\), which is below \(5\times10^{-8}\). This result crosses the stated genome-wide threshold. A 95% Wald confidence interval is

$$ 0.080\pm1.96(0.014) =0.080\pm0.02744 =(0.0526,\ 0.1074). $$

On this standardized scale, the estimated association is modest: about 0.080 standard deviations per additional effect allele. The interval describes values reasonably compatible with the data under the model, and is narrow enough to locate the association's scale fairly precisely. The small p-value is strong evidence against the zero-effect null under the stated model; it does not convert the modest effect into a large one.

Worked Example: Smaller P-Value Does Not Mean Larger Effect

Consider two hypothetical variant results for the same standardized quantitative trait and comparable additive models. Assume the same model conditions as above. Variant A has \(\hat{\beta}=0.040\) standard deviations per allele and \(SE=0.006\). Variant B has \(\hat{\beta}=0.200\) standard deviations per allele and \(SE=0.050\). Calculate each Wald statistic and compare.

For A,

$$ Z_A=\frac{0.040}{0.006}=6.667, \qquad p_A\approx2.6\times10^{-11}. $$

For B,

$$ Z_B=\frac{0.200}{0.050}=4.000, \qquad p_B\approx6.33\times10^{-5}. $$

Variant B has the larger estimated effect, five times the estimate for A. Yet A has the smaller p-value because its estimate is much more precise relative to its size. Under a \(5\times10^{-8}\) cutoff, A crosses the threshold and B does not. Their 95% Wald intervals make the different uncertainties visible:

$$ \text{A: }0.040\pm1.96(0.006)=(0.0282,\ 0.0518), \qquad \text{B: }0.200\pm1.96(0.050)=(0.102,\ 0.298). $$

The results do not show that A is more biologically important than B. They show stronger statistical evidence against a zero-effect null for A in these data, while B has a larger estimated effect and greater uncertainty.

Effect Estimates and Confidence Intervals

An estimated effect needs a scale and a direction. For a quantitative trait, \(\hat{\beta}\) might be the mean trait difference per additional allele, measured in trait units or standard deviations. For another outcome, the association model may use a different scale. A p-value alone does not supply that information. Reporting the estimate with its units, standard error, and interval makes the result interpretable beyond the threshold decision.

For a large-sample Wald test of \(H_0:\beta=0\), the usual two-sided 95% Wald interval is \(\hat{\beta}\pm1.96SE\). Under the same approximation, zero is outside this interval exactly when \(|\hat{\beta}/SE|>1.96\), corresponding to a two-sided p-value below approximately 0.05. This relationship is a feature of that test and interval construction; it does not mean that an interval excluding zero is genome-wide significant. A genome-wide cutoff is much more stringent than 0.05.

An interval is also more informative than a binary threshold decision when the estimate is imprecise. A narrow interval can rule out many effect sizes, while a wide one may include both negligible and potentially meaningful effects. Neither interval width nor p-value settles whether the effect matters clinically or biologically; that judgment requires a relevant scale and substantive context.

Worked Example: Reading a Discovery Result Alongside Replication

Worked Example: A Replication Result Adds Context

Suppose a hypothetical discovery GWAS estimates an effect of \(0.100\) standard deviations per allele, with \(SE=0.016\). A separate cohort then estimates the effect for the same allele and trait as \(0.080\), with \(SE=0.030\). Assume both analyses use comparable scales, correctly aligned alleles, suitable association models, and valid large-sample Wald standard errors. The discovery family uses a prespecified \(5\times10^{-8}\) cutoff.

In discovery,

$$ Z_{\mathrm{disc}}=\frac{0.100}{0.016}=6.25, \qquad p_{\mathrm{disc}}\approx4.1\times10^{-10}. $$

The discovery result passes the stated genome-wide cutoff. Its 95% interval is \(0.100\pm1.96(0.016)=(0.0686,\ 0.131)\) standard deviations per allele.

In the separate cohort,

$$ Z_{\mathrm{rep}}=\frac{0.080}{0.030}=2.667, \qquad p_{\mathrm{rep}}\approx0.00766. $$

The replication estimate has the same direction, and its 95% interval is \(0.080\pm1.96(0.030)=(0.0212,\ 0.139)\) standard deviations per allele. This result is nominally inconsistent with a zero-effect null at the 0.05 level under the stated two-sided test, but it does not meet the discovery study's genome-wide cutoff. Whether it qualifies as successful replication depends on the replication plan, including its prespecified hypotheses, error control, and criteria. The result adds supportive evidence in a separate cohort, but it does not by itself establish that the effect is true, causal, or exactly the same size in both cohorts.

Why the Distinction Matters

A significance threshold is useful because it makes a decision rule explicit in a large search. But reducing a result to “significant” or “not significant” discards information. A result just below a cutoff is not categorically different in evidential content from one just above it; the cutoff is a chosen boundary for a decision, not a natural dividing line between true and false associations. Likewise, failure to cross a stringent threshold does not prove no association exists. The estimate and interval show what effect sizes remain compatible with the data.

Replication is valuable because evidence in a separate cohort can test whether a result is seen again, rather than relying only on the discovery scan. It should be interpreted on a comparable allele and phenotype scale and with attention to its own uncertainty. A similar direction and plausible effect estimate are informative, but differences in precision mean that p-values can differ even when estimates are similar. A replication p-value should be judged against the replication plan, not automatically against the discovery threshold.

Key takeaway: State the testing family and prespecified threshold, then report the p-value, effect estimate with units, uncertainty interval, and replication evidence. Threshold crossing is a multiplicity-aware decision; the p-value, effect size, and precision answer related but distinct questions.

Common Mistake

Wrong reasoning: “Variant A has the smaller p-value, so it must have the larger and more important genetic effect.” This confuses evidence against a null with effect magnitude. A p-value depends on both the estimate and its standard error, as \(Z=\hat{\beta}/SE\) shows. A precise small estimate can have a smaller p-value than a larger, uncertain estimate. The correction is to compare effect estimates on the same scale, inspect their intervals, and use the p-value to describe evidence against the specified null—not as a ranking of biological importance.

Check Your Understanding

Answer each question by distinguishing the testing decision from the association estimate.

  1. In a genome-wide scan with a prespecified \(5\times10^{-8}\) cutoff, what does a p-value of \(2\times10^{-8}\) indicate, and what does it not indicate?
  2. Two variants have estimates of 0.03 and 0.15 standard deviations per allele. Why could the smaller estimate have the smaller p-value?
  3. For a two-sided Wald test, what does a 95% interval that excludes zero imply under the same large-sample approximation? Does it establish genome-wide significance?
  4. Why should the testing family be defined before results are examined?
  5. A separate cohort gives a same-direction estimate with a nominal p-value below 0.05. What additional information is needed before calling the finding successful replication?
Clinical Biostats